Propranolol Hydrochloride (Page 5 of 6)
Cardiovascular
Bradycardia; congestive heart failure; intensification of AV block; hypotension; paresthesia of hands; thrombocytopenic purpura; arterial insufficiency, usually of the Raynaud type.
Central Nervous System
Light-headedness; mental depression manifested by insomnia, lassitude, weakness, fatigue; catatonia; visual disturbances; hallucinations; vivid dreams; an acute reversible syndrome characterized by disorientation for time and place, short-term memory loss, emotional lability, slightly clouded sensorium, and decreased performance on neuropsychometrics. For immediate release formulations, fatigue, lethargy, and vivid dreams appear dose related.
Gastrointestinal: Nausea, vomiting, epigastric distress, abdominal cramping, diarrhea, constipation, mesenteric arterial thrombosis, ischemic colitis.
Allergic: Hypersensitivity reactions, including anaphylactic/anaphylactoid reactions; pharyngitis and agranulocytosis; erythematous rash; fever combined with aching and sore throat; laryngospasm; respiratory distress.
Respiratory: Bronchospasm.
Hematologic: Agranulocytosis, nonthrombocytopenic purpura, thrombocytopenic purpura.
Autoimmune: Systemic lupus erythematosus (SLE).
Skin and Mucous Membranes: Stevens-Johnson Syndrome, toxic epidermal necrolysis, dry eyes, exfoliative dermatitis, erythema multiforme, urticaria, alopecia, SLE-like reactions, and psoriasiform rashes. Oculomucocutaneous syndrome involving the skin, serous membranes, and conjunctivae reported for a beta-blocker (practolol) have not been associated with propranolol.
Genitourinary: Male impotence; Peyronie’s disease.
OVERDOSAGE
Propranolol is not significantly dialyzable. In the event of overdosage or exaggerated response, the following measures should be employed:
General
If ingestion is or may have been recent, evacuate gastric contents, taking care to prevent pulmonary aspiration.
Supportive Therapy
Hypotension and bradycardia have been reported following propranolol overdose and should be treated appropriately. Glucagon can exert potent inotropic and chronotropic effects and may be particularly useful for the treatment of hypotension or depressed myocardial function after a propranolol overdose. Glucagon should be administered as 50-150 mcg/kg intravenously followed by continuous drip of 1-5 mg/hour for positive chronotropic effect. Isoproterenol, dopamine or phosphodiesterase inhibitors may also be useful. Epinephrine, however, may provoke uncontrolled hypertension. Bradycardia can be treated with atropine or isoproterenol. Serious bradycardia may require temporary cardiac pacing.
The electrocardiogram, pulse, blood pressure, neurobehavioral status and intake and output balance must be monitored. Isoproterenol and aminophylline may be used for bronchospasm.
To report SUSPECTED ADVERSE REACTIONS contact AvKARE, Inc. at 1-855-361-3993; email
drugsafety@avkare.com; or FDA at 1-800-FDA-1088 or
www.fda.gov/medwatch.
DOSAGE AND ADMINISTRATION
General
Propranolol Hydrochloride Extended-Release Capsules, USP, provide propranolol hydrochloride in a sustained-release capsule for administration once daily. If patients are switched from propranolol hydrochloride tablets to Propranolol Hydrochloride Extended-Release Capsules, USP, care should be taken to assure that the desired therapeutic effect is maintained. Propranolol Hydrochloride Extended-Release Capsules, USP, should not be considered a simple mg-for-mg substitute for propranolol hydrochloride tablets. Propranolol Hydrochloride Extended-Release Capsules, USP, have different kinetics and produces lower blood levels. Retitration may be necessary, especially to maintain effectiveness at the end of the 24-hour dosing interval.
Hypertension
The usual initial dosage is 80 mg Propranolol Hydrochloride Extended-Release Capsules, USP, once daily, whether used alone or added to a diuretic. The dosage may be increased to 120 mg once daily or higher until adequate blood pressure control is achieved. The usual maintenance dosage is 120 to 160 mg once daily. In some instances a dosage of 640 mg may be required. The time needed for full hypertensive response to a given dosage is variable and may range from a few days to several weeks.
Angina Pectoris
Starting with 80 mg Propranolol Hydrochloride Extended-Release Capsules, USP, once daily, dosage should be gradually increased at three- to seven-day intervals until optimal response is obtained. Although individual patients may respond at any dosage level, the average optimal dosage appears to be 160 mg once daily. In angina pectoris, the value and safety of dosage exceeding 320 mg per day have not been established.
If treatment is to be discontinued, reduce dosage gradually over a period of a few weeks (see WARNINGS).
Migraine
The initial oral dose is 80 mg Propranolol Hydrochloride Extended-Release Capsules, USP, once daily. The usual effective dose range is 160 to 240 mg once daily. The dosage may be increased gradually to achieve optimal migraine prophylaxis. If a satisfactory response is not obtained within four to six weeks after reaching the maximal dose, Propranolol Hydrochloride Extended-Release Capsules, USP, therapy should be discontinued. It may be advisable to withdraw the drug gradually over a period of several weeks depending on the patient’s age, comorbidity, and dose of Propranolol Hydrochloride Extended-Release Capsules, USP.
Hypertrophic Subaortic Stenosis
The usual dosage is 80 to 160 mg Propranolol Hydrochloride Extended-Release Capsules, USP, once daily.
HOW SUPPLIED
Propranolol Hydrochloride Extended-Release Capsules, USP.
Each white/opaque capsule, imprinted with “60”on cap and “RD203” on body contains 60 mg of propranolol hydrochloride in bottles of 100 (NDC 42291-522-01) and bottles of 1000 (NDC 42291-522-10)
Each capsule with white/opaque body and orange/opaque cap, imprinted with “80”on cap and “RD203” on body contains 80 mg of propranolol hydrochloride in bottles of 100 (NDC 42291-523-01) and bottles of 1000 (NDC 42291-523-10)
Each orange/opaque capsule, imprinted with “120”on cap and “RD203” on body contains 120 mg of propranolol hydrochloride in bottles of 100 (NDC 42291-524-01) and bottles of 1000 (NDC 42291-524-10).
Each light brown/opaque capsule, imprinted with “160”on cap and “RD203” on body contains 160 mg of propranolol hydrochloride in bottles of 100 (NDC 42291-525-01) and bottles of 1000 (NDC 42291-525-10).
Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].
Protect from light, moisture, freezing, and excessive heat.
Dispense in a tight, light-resistant container as defined in the USP.
Propranolol Hydrochloride Extended-Release Capsules, USP, a DIFFUCAPS ® drug delivery product, manufactured by Adare Pharmaceuticals, Inc.
You can also ask your doctor or pharmacist for information about Propranolol Hydrochloride Extended-Release Capsules, USP that is written for healthcare professionals. For more information, call 1-855-361-3993 or go to www.avkare.com.
Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
Mfg. Rev. 09/15
AV Rev. 07/17 (P)
PRINCIPAL DISPLAY PANEL — 60 mg Capsule Bottle Label
AvKARE
NDC 42291-522-01
Propranolol
Hydrochloride
Extended-Release
Capsules, USP
60 mg
100 Capsules
Rx Only
Usual Dosage: See package insert for full prescribing information.
Each extended-release capsule contains 60 mg of propranolol hydrochloride.
Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F). [See USP Controlled Room
Temperature].
Protect from light, moisture, freezing, and excessive heat.
Dispense in a tight, light-resistant container as defined in the USP.
Keep out of the reach of children.
Propranolol Hydrochloride Extended-Release Capsules, USP, a DIFFUCAPS® drug delivery product, manufactured by Adare Pharmaceuticals, Inc.
Manufactured for:
AvKARE, Inc.
Pulaski, TN 38478
Mfg. Iss. 09/15 AV 05/17 (P)
N3 4229152201 5
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.
https://medlibrary.org/lib/rx/meds/propranolol-hydrochloride-60/page/5/